PERLARA, PBC
AI-driven translational science platform for rare metabolic disease drug discovery and development
- Sector
- Biotech
- Headquarters
- SAN FRANCISCO, CA
- Founded
- 2014
- Latest Form D
- $4.1M, Aug 2017
- Total capital
- $6M
- Federal grants
- $1M
- 1 award · 2025
- Rank in peer group#17 of 37
- Private capital raised
- $4.9M
- 2 Form D · last Aug 2017
- 110 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 5 pending · first 2019
- Rank in peer group#8 of 37
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · REMIT (Rescue Mitochondrial Therapeutics): Unlocking Broad-Spectrum Mitochondrial Rescuers$1M
- Private capital raisedForm D · SEC · 2nd filing$4.1M
- Private capital raisedForm D · SEC · 1st filing$800K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 37 peers
Line = medianBiotech · Platform
- Federal grants#17 · top 46%
- Granted patents#8 · top 22%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Ethan O PerlsteinResearcherExecutive Officer, Director, PromoterLinked by $1M in grants as PI
- Linda O AveyDirectorNamed in SEC Form D filings
- Matthew O WilseyDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 6- GrantedPHARMACEUTICAL FORMULATIONS COMPRISING SUBSTITUTED PYRAZOLO[5,1-c]PYRIDO[4,3-e][1,2,4]TRIAZINES FOR TREATING LYSOSOMAL STORAGE DISORDERSUSPTOUS 10,166,236
- PendingMethods For Treating Dhdds-related DisordersUSPTOApplication 63701223
- PendingMethods For Treating Congenital Disorders Of GlycosylationUSPTOApplication 62760311
Show all 6 patent records
- PHARMACEUTICAL FORMULATIONS COMPRISING SUBSTITUTED PYRAZOLO[5,1-c]PYRIDO[4,3-e][1,2,4]TRIAZINES FOR TREATING LYSOSOMAL STORAGE DISORDERSJan 1, 2019 · US 10,166,236Granted
- Methods For Treating Dhdds-related DisordersApplication 63701223Pending
- Methods For Treating Congenital Disorders Of GlycosylationApplication 62760311Pending
- Methods For Treating Congenital Disorders Of GlycosylationApplication 62730974Pending
- Methods for treating congenital disorders of glycosylationApplication 62765356Pending
- Fused Heterocyclic Organic Compounds And Uses ThereofApplication PCTUS2017023244Pending
Related companies, and why
- Superior Genomics, Inc.Similar federal contract value in Biotech · null in contracts
- CONCEPTION HOLDINGS, INC.Similar federal contract value in Biotech · null in contracts
- SOLUBLE THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Entelo, Inc.Similar federal contract value in Biotech · null in contracts
- Lipogene Company, Inc., TheSimilar federal contract value in Biotech · null in contracts
- ANTHROBIO, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .